MRTX insider transaction filings
Mirati Therapeutics, Inc. — 33 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2024-01-25. Screen MRTX transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for MRTX between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Mirati Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-01-25 | 4 | Boxer Capital, LLC Boxer Asset Management Inc. LEWIS JOSEPH MVA Investors, LLC Davis Aaron I. Dissanayake Shehan Bharatha Fuglesang Christopher Braslyn Ltd. Lockend Five, LLC | Disposition to issuer (D): 287,866 · Disposition to issuer (D): 3,201,440 · Disposition to issuer (D): 203,754 · Disposition to issuer (D): 3,135,966 · Disposition to issuer (D): 30,518 · Disposition to issuer (D): 332,809 (derivative) · +2 more | EDGAR |
| 2024-01-23 | 4 | Martinez Maria E — Director | Disposition to issuer (D): 6,021 · Disposition to issuer (D): 4,444 · Disposition to issuer (D): 6,808 · Disposition to issuer (D): 17,500 (derivative) · Disposition to issuer (D): 7,520 (derivative) · Disposition to issuer (D): 11,000 (derivative) | EDGAR |
| 2024-01-23 | 4 | Cherrington Julie M — Director | Disposition to issuer (D): 4,444 · Disposition to issuer (D): 6,808 · Disposition to issuer (D): 7,520 (derivative) | EDGAR |
| 2024-01-23 | 4 | Ondrey Aaron — Chief Financial Officer | Disposition to issuer (D): 1,302 · Disposition to issuer (D): 21,138 · Disposition to issuer (D): 17,021 · Disposition to issuer (D): 6,817 (derivative) · Disposition to issuer (D): 5,027 (derivative) · Disposition to issuer (D): 11,993 (derivative) | EDGAR |
| 2024-01-23 | 4 | Hickey Benjamin — EVP, Chief Commercial Officer | Disposition to issuer (D): 27,801 · Disposition to issuer (D): 72,206 · Disposition to issuer (D): 17,021 · Disposition to issuer (D): 2,128 (derivative) · Disposition to issuer (D): 43,328 (derivative) | EDGAR |
| 2024-01-23 | 4 | Sandler Alan B. — Chief Medical Officer | Disposition to issuer (D): 10,547 · Disposition to issuer (D): 52,297 · Disposition to issuer (D): 17,021 · Disposition to issuer (D): 65,000 (derivative) | EDGAR |
| 2024-01-23 | 4 | Christensen Jamie — EVP & Chief Scientific Officer | Disposition to issuer (D): 56,495 · Disposition to issuer (D): 81,480 · Disposition to issuer (D): 17,021 · Disposition to issuer (D): 1,042 (derivative) · Disposition to issuer (D): 20,715 (derivative) · Disposition to issuer (D): 8,747 (derivative) · +11 more | EDGAR |
| 2024-01-23 | 4 | BAUM CHARLES M — Founder, President, and CEO, Director | Disposition to issuer (D): 123,389 · Disposition to issuer (D): 94,057 · Disposition to issuer (D): 20,425 · Disposition to issuer (D): 100,273 (derivative) · Disposition to issuer (D): 69,258 (derivative) · Disposition to issuer (D): 81,458 (derivative) · +5 more | EDGAR |
| 2024-01-23 | 4 | Moriarty John B — Chief Legal Officer | Disposition to issuer (D): 675 · Disposition to issuer (D): 71,660 · Disposition to issuer (D): 83,525 (derivative) | EDGAR |
| 2024-01-23 | 4 | Davis Aaron I. — Director | Disposition to issuer (D): 43,073 · Disposition to issuer (D): 4,444 · Disposition to issuer (D): 6,808 · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 7,520 (derivative) · Disposition to issuer (D): 11,000 (derivative) | EDGAR |
| 2024-01-23 | 4 | Sharp Shalini — Director | Disposition to issuer (D): 4,162 · Disposition to issuer (D): 5,252 · Disposition to issuer (D): 6,808 · Disposition to issuer (D): 7,520 (derivative) | EDGAR |
| 2024-01-23 | 4 | Johnson Craig A — Director | Disposition to issuer (D): 6,021 · Disposition to issuer (D): 4,444 · Disposition to issuer (D): 6,808 · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 18,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · +2 more | EDGAR |
| 2024-01-23 | 4 | Hasnain Faheem — Director | Disposition to issuer (D): 8,717 · Disposition to issuer (D): 6,333 · Disposition to issuer (D): 9,702 · Disposition to issuer (D): 35,000 (derivative) · Disposition to issuer (D): 10,716 (derivative) · Disposition to issuer (D): 10,000 (derivative) | EDGAR |
| 2024-01-23 | 4 | Gallagher Carol Giltner — Director | Disposition to issuer (D): 7,555 · Disposition to issuer (D): 6,808 · Disposition to issuer (D): 12,784 (derivative) | EDGAR |
| 2024-01-23 | 4 | CARTER BRUCE L A — Director | Disposition to issuer (D): 6,021 · Disposition to issuer (D): 4,444 · Disposition to issuer (D): 6,808 · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 7,520 (derivative) · Disposition to issuer (D): 11,000 (derivative) | EDGAR |
| 2024-01-18 | 4 | Hickey Benjamin — EVP, Chief Commercial Officer | Sale (S): 966 @ $59.02 · Sale (S): 631 @ $59.02 | EDGAR |
| 2024-01-18 | 4 | Christensen Jamie — EVP & Chief Scientific Officer | Sale (S): 966 @ $59.02 · Sale (S): 631 @ $59.02 | EDGAR |
| 2024-01-09 | 4 | Hickey Benjamin — EVP, Chief Commercial Officer | Sale (S): 2,090 @ $58.92 | EDGAR |
| 2024-01-05 | 4 | Christensen Jamie — EVP & Chief Scientific Officer | Sale (S): 1,531 @ $58.81 | EDGAR |
| 2024-01-03 | 4 | Cherrington Julie M — Director | Grant/award (A): 6,808 @ $58.75 | EDGAR |
| 2024-01-03 | 4 | Hickey Benjamin — EVP, Chief Commercial Officer | Grant/award (A): 17,021 @ $58.75 | EDGAR |
| 2024-01-03 | 4 | Christensen Jamie — EVP & Chief Scientific Officer | Grant/award (A): 17,021 @ $58.75 | EDGAR |
| 2024-01-03 | 4 | Sandler Alan B. — Chief Medical Officer | Grant/award (A): 17,021 @ $58.75 | EDGAR |
| 2024-01-03 | 4 | Ondrey Aaron — CFO | Grant/award (A): 17,021 @ $58.75 | EDGAR |
| 2024-01-03 | 4 | BAUM CHARLES M — Interim CEO, Director | Grant/award (A): 20,425 @ $58.75 | EDGAR |
| 2024-01-03 | 4 | Martinez Maria E — Director | Grant/award (A): 6,808 @ $58.75 | EDGAR |
| 2024-01-03 | 4 | Davis Aaron I. — Director | Grant/award (A): 6,808 @ $58.75 | EDGAR |
| 2024-01-03 | 4 | Sharp Shalini — Director | Grant/award (A): 6,808 @ $58.75 | EDGAR |
| 2024-01-03 | 4 | Johnson Craig A — Director | Grant/award (A): 6,808 @ $58.75 | EDGAR |
| 2024-01-03 | 4 | Hasnain Faheem — Director | Grant/award (A): 9,702 @ $58.75 | EDGAR |
| 2024-01-03 | 4 | Gallagher Carol Giltner — Director | Grant/award (A): 6,808 @ $58.75 | EDGAR |
| 2024-01-03 | 4 | CARTER BRUCE L A — Director | Grant/award (A): 6,808 @ $58.75 | EDGAR |
| 2023-12-19 | 4 | Christensen Jamie — EVP & Chief Scientific Officer | Sale (S): 2,387 @ $57.50 | EDGAR |
Recent 8-K events — Mirati Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2024-01-23 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-12-19 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MRTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →